0.45
-2.69%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Doxa
Its shares trade on Nasdaq Stockholm under the ticker DOXA.ST. It has been listed since 7 April 2014. In the fiscal year to 31 December 2025, it reported revenue of SEK 63.5m and a net loss of SEK 335.5m. At that date it held total assets of SEK 4.03bn and shareholders' equity of SEK 1.97bn.
Doxa AB engages in the development, manufacture, and commercialization of bioceramic dental products. The company is headquartered in Malmo, Skane. The company went IPO on 2014-04-07. The firm develops, manufactures and commercializes products based upon its technology platform of calcium aluminate hydrate and bioactive ceramics. Activities are divided into the therapy areas of orthopedics and odontology. Research areas within orthopedics are methods for treating fractures resulting from osteoporosis, reconstructive orthopedics and coating of implants. Research areas within odontology are tooth restoration and implant fixation.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Industrials
- Industry
- Construction & Engineering
- Listed since
- 7 Apr 2014
- Website
- doxa.se ↗
Leadership
Pay as last reported
- Mr. Greg DingizianChairman of the Board$263,000
- Mr. Christian LindgrenPresident, Chief Executive Officer, Acting Chief Financial Officer, Director, since 2019$121,000
- Mr. Per EkelundIndependent Vice Chairman of the Board$121,000
- Mr. Mikael AhlbornProperty Manager
- Ms. Lena GrimslaettDirector
- Mr. Magnus KochDirector
- Mr. Lars KongstadDirector
- Mr. Anders PetterssonIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Doxa AB develops bioceramic dental products using calcium aluminate hydrate technology.
- The company focuses on orthopedics and odontology therapy areas for innovative medical solutions.
- Doxa AB's IPO on April 7, 2014, established a strong market presence in the construction sector.
Weaknesses
- Doxa AB's business is limited to bioceramic dental products without diversification into other medical fields.
- The company's research in orthopedics focuses on osteoporosis fracture treatments, which may limit market expansion.
- Doxa AB's operations are based in Malmö, Skane, potentially restricting geographic reach.
Opportunities
- Doxa AB can expand its dental product line to include new applications in tooth restoration and implant fixation.
- The growing demand for bioceramic solutions in orthopedics offers significant market potential.
- Doxa AB's technology platform could be leveraged for new product development in the construction industry.
Threats
- Doxa AB faces competition from established dental product manufacturers in the global market.
- Regulatory changes in the healthcare sector could impact the commercialization of bioceramic products.
- Doxa AB's reliance on a single technology platform may pose risks if alternative solutions emerge.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.